Analytical Validation and Clinical Implementation of MedGenome HRD Assay: A Large Comparative Study Against Commercial HRD Assays in Ovarian Cancer
- 1Department of Molecular Oncopathology, MedGenome Labs Limited., Bangalore, Karnataka, India
Abstract
Background: Homologous recombination deficiency (HRD) is an important predictive biomarker for poly (ADP-ribose) polymerase inhibitor (PARPi) therapy in ovarian cancer (OC). However, real-world data on HRD prevalence and assay performance in Indian patients are limited. This study evaluated commercial HRD assays, then developed an in-house HRD assay and characterized HRD and BRCA alterations in a large real-world Indian OC cohort. Methods: This retrospective study included 4,163 formalin-fixed paraffin-embedded (FFPE) OC samples tested between 2021 and 2025. HRD and BRCA status were initially assessed using the AmoyDx HRD Focus Panel (n=1,097) and SOPHiA DDM HRD Solution (n=470). Subsequently, 170 representative samples were used for the development and validation of an in-house HRD assay (MG_HRD), with external concordance assessed using the Myriad myChoice CDx assay in a subset of samples. Following validation, MG_HRD was implemented in routine clinical practice and applied to an independent cohort of 2,596 OC samples. HRD prevalence, BRCA mutation status, and clinicopathological associations were evaluated in all cohorts. Results: Among 4,163 ovarian cancer samples, HRD positivity was observed in 52.4% of cases, and pathogenic/likely pathogenic BRCA1/2 variants were identified in 23.6% of cases. Notably, 28.8% of tumors were BRCA wild-type but HRD-positive. BRCA-mutated tumors demonstrated significantly higher HRD genomic instability scores than BRCA wild-type tumors (p<0.001). HRD positivity was significantly enriched in high grade serous ovarian carcinomas. Remarkably, the BRCA1 c.68_69del (p.Glu23ValfsTer17) founder mutation was detected in 14.2% (97/685) of cases among the pathogenic variants in our study. The MG_HRD assay showed excellent concordance with commercial assays, achieving 97.1% overall agreement, 98.3% negative percent agreement (NPA), and 96.4% positive percent agreement (PPA), with complete concordance observed in the externally evaluated Myriad subset. Conclusions: This is the first Indian study to develop, validate, and implement an in-house HRD assay and evaluate HRD across three testing platforms in a large real-world OC cohort. The high prevalence of BRCA wild-type/HRD-positive tumors highlight the importance of comprehensive HRD testing, whereas the strong performance of MG_HRD supports its use as a reliable and cost-effective alternative for routine clinical practice. Keywords: ovarian cancer; homologous recombination deficiency; genomic instability, BRCA1/2, mutation, high grade serous carcinoma
Related
- Process-dependent Analytical Differences Among Commercial Botulinum Neurotoxin Type A Formulations
- Analytical Agreement and Diagnostic Performance of a Commercial Point-of-Care Lipid Testing System for Lipid Profile and Atherogenic Ratios
- Identification and validation of feature genes using a ferroptosis-informed analytical framework in medulloblastoma
- Analytical and clinical validation of the EdenDx methylation assay as a noninvasive supportive triage tool for early detection of endometrial cancer in cervical scraping specimens
- Photographic Atlas for Cosmetic Noodling Characterization: Development, Analytical Validation, and Consumer Perception
BibTeX
@misc{rehman2026analytical,
title = {{Analytical Validation and Clinical Implementation of MedGenome HRD Assay: A Large Comparative Study Against Commercial HRD Assays in Ovarian Cancer}},
author = {S. M. Rehman and R. Shetty and C. M. Magdalene and M. Panda and J. S. Ganesh and R. Gupta and S. Murugan and V. L. Ramprasad and B. N Dhabar and S. Patil and A. Kapoor and S. Aggarwal and T. Patil and A. Pai and K. Prasad and S. K. Mishra and V. Sathyanarayanan and R. Pramanik and A. Gupta and B. Sansar},
howpublished = {medRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.02.26367052},
url = {https://www.medrxiv.org/content/10.64898/2026.11.02.26367052v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Analytical Validation and Clinical Implementation of MedGenome HRD Assay: A Large Comparative Study Against Commercial HRD Assays in Ovarian Cancer
AU - S. M. Rehman
AU - R. Shetty
AU - C. M. Magdalene
AU - M. Panda
AU - J. S. Ganesh
AU - R. Gupta
AU - S. Murugan
AU - V. L. Ramprasad
AU - B. N Dhabar
AU - S. Patil
AU - A. Kapoor
AU - S. Aggarwal
AU - T. Patil
AU - A. Pai
AU - K. Prasad
AU - S. K. Mishra
AU - V. Sathyanarayanan
AU - R. Pramanik
AU - A. Gupta
AU - B. Sansar
PY - 2026
DA - 2026/11/02
PB - medRxiv
DO - 10.64898/2026.11.02.26367052
UR - https://www.medrxiv.org/content/10.64898/2026.11.02.26367052v1
AB - Background: Homologous recombination deficiency (HRD) is an important predictive biomarker for poly (ADP-ribose) polymerase inhibitor (PARPi) therapy in ovarian cancer (OC). However, real-world data on HRD prevalence and assay performance in Indian patients are limited. This study evaluated commercial HRD assays, then developed an in-house HRD assay and characterized HRD and BRCA alterations in a large real-world Indian OC cohort. Methods: This retrospective study included 4,163 formalin-fixed paraffin-embedded (FFPE) OC samples tested between 2021 and 2025. HRD and BRCA status were initially assessed using the AmoyDx HRD Focus Panel (n=1,097) and SOPHiA DDM HRD Solution (n=470). Subsequently, 170 representative samples were used for the development and validation of an in-house HRD assay (MG_HRD), with external concordance assessed using the Myriad myChoice CDx assay in a subset of samples. Following validation, MG_HRD was implemented in routine clinical practice and applied to an independent cohort of 2,596 OC samples. HRD prevalence, BRCA mutation status, and clinicopathological associations were evaluated in all cohorts. Results: Among 4,163 ovarian cancer samples, HRD positivity was observed in 52.4% of cases, and pathogenic/likely pathogenic BRCA1/2 variants were identified in 23.6% of cases. Notably, 28.8% of tumors were BRCA wild-type but HRD-positive. BRCA-mutated tumors demonstrated significantly higher HRD genomic instability scores than BRCA wild-type tumors (p<0.001). HRD positivity was significantly enriched in high grade serous ovarian carcinomas. Remarkably, the BRCA1 c.68_69del (p.Glu23ValfsTer17) founder mutation was detected in 14.2% (97/685) of cases among the pathogenic variants in our study. The MG_HRD assay showed excellent concordance with commercial assays, achieving 97.1% overall agreement, 98.3% negative percent agreement (NPA), and 96.4% positive percent agreement (PPA), with complete concordance observed in the externally evaluated Myriad subset. Conclusions: This is the first Indian study to develop, validate, and implement an in-house HRD assay and evaluate HRD across three testing platforms in a large real-world OC cohort. The high prevalence of BRCA wild-type/HRD-positive tumors highlight the importance of comprehensive HRD testing, whereas the strong performance of MG_HRD supports its use as a reliable and cost-effective alternative for routine clinical practice. Keywords: ovarian cancer; homologous recombination deficiency; genomic instability, BRCA1/2, mutation, high grade serous carcinoma
ER -